Abstract 110P
Background
Conversion therapy is an important treatment for patients with initial unresectable metastatic colorectal cancer(mCRC) to achieve radical resection. Circulating tumor cells (CTC) are one of the important liquid biopsy methods. There is no study to explore their clinical value in predicting the efficacy. The aim of this study is to explore the value of the number and morphology of CTC in predicting the efficacy of conversion therapy in initial unresectable mCRC patients.
Methods
This study prospectively collected eligible patients with initially unresectable mCRC who were initially diagnosed in Zhongshan Hospital from November 2020 to June 2021. At baseline, after treatment, and before and after conversion resection, multi-point blood sampling was performed. CTC detection using ChimeraX ® Platform; Morphological typing is based on the CTC morphological data of 2083 patients with colorectal cancer who underwent CTC detection in Zhongshan Hospital. Cell Profiler is used for cell feature assignment, clustering and typing.
Results
A total of 126 eligible patients with mCRC participated in this study. According to morphology, CTC can be divided into four morphological types: T1-T4. All 126 patients underwent baseline CTC testing, and 103 patients underwent CTC testing after conversion therapy. After conversion therapy, the positive rate and detection number of CTC significantly decreased (85.7% vs 60.2%, 1.71 vs 1.15, P=0.0052); The detection number of T3 and T4 subtypes significantly decreased (T3: 0.87 vs 0.52, P=0.0026, T4: 0.25 vs 0.06, P<0.0001). The objective response rate was significantly correlated with the baseline number of CTCs (69.8% vs 50.8%, P=0.029), but not significantly with the number of CTCs after treatment. The objective response rate of patients with T3T4 dominance was significantly higher than that of patients with T1T2 dominance (67.6% vs 47.1%, P=0.042). The number of CTC was correlated with patient progression free survival, and baseline CTC positive patients had a worse prognosis (P=0.0012).
Conclusions
The number and morphology of CTCs have good therapeutic and prognostic value for patients with initial unresectable mCRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract